Online inquiry

IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8366MR)

This product GTTS-WQ8366MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TACSTD2 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002353.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4070
UniProt ID P09758
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8366MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3197MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ15843MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ2397MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 110
GTTS-WQ4860MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ2191MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ11031MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCLA-128
GTTS-WQ11843MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MK-7684
GTTS-WQ10858MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA M9346A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW